glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Early advocates included bioinformaticians in Cambridge, UK, where there were many early bioinformatics labs such as the MRC centre, Sanger centre, and EBI (European Bioinformatics Institute); for example, the MRC centre carried out the first genome and proteome projects.
In February 2016, a Higher School of Economics university academic and Harvard University visiting scholar Yuval Weber wrote on E-International Relations that "the world is not entering Cold War II", stating that the current tensions and ideologies of Russia and Western countries are not similar to those of the original Cold War, that conflicts in Europe and the Middle East do not destabilise other areas geographically, and that Russia "is far more integrated with the outside world than the Soviet Union ever was". However, he suggested that Russia and the West were in the midst of a "mini-Cold War".
The requirement of arginine in the urea cycle is reduced, as dogs have a functional pyrroline-5-carboxylate synthase. Dogs have a functional delta 6 desaturase, hence no specific need for arachidonic acid. Dogs have a functional sulfinoalanine decarboxylase and can synthesise taurine from methionine and cysteine; however, some breeds have a genetic predisposition to taurine deficiency. Taurine supplementation is recommended for dogs at risk of taurine deficiency and dogs with dilated cardiomyopathy. Unlike cats, dogs and humans can use Vitamin D2 nearly as efficiently as they use Vitamin D3.
== Isosceles triangle == If the two equal sides of an isosceles triangle have length a and the other side has length c, then the internal angle bisector t from one of the two equal-angled vertices satisfies
Sources: en.wikipedia.org
MacLeod was overseeing the work of Banting, who had no experience in physiology, and his assistant Best. In December 1921, when Banting and Best were having difficulties in refining the pancreatic extract and monitoring glucose levels, MacLeod assigned the biochemist James Collip to the team. In January 1922, while Collip was working on insulin purification, Best and Banting administered prematurely their pancreatic extracts to 14-year-old Leonard Thompson, who suffered a severe allergic reaction. Eventually, Collip succeeded in preparing insulin in a more pure, usable form. Banting, Best and Collip shared the patent for insulin, which they sold to the University of Toronto for one dollar. In 1923, the Nobel Prize Committee honoured Banting and John Macleod with the Nobel Prize in Medicine for the discovery of insulin, ignoring Best and Collip. Banting chose to share half of the prize money with Best. The key contribution by Collip was recognised in the Nobel speech of MacLeod, who also gave one-half of his prize money to Collip. However, "if Banting was hoping that this might offer Best some consolation for not having shared in the prize, he was mistaken. Best’s resentment at having been overlooked began to irritate Banting", to the point that Banting stated in 1941 "If I don’t come back and they give my [Professorial] Chair to that son-of-a-bitch Best, I’ll never rest in my grave", shortly before Banting boarded a plane for the UK which crashed and killed him.
The waning loyalty of the Cossacks, and the szlachta's arrogance towards them, resulted in several Cossack uprisings against the Polish–Lithuanian Commonwealth in the early 17th century. Finally, the King's adamant refusal to accede to the demand to expand the Cossack Registry prompted the largest and most successful of these: the Khmelnytsky Uprising, that began in 1648. Some Cossacks, including the Polish szlachta in Ukraine, converted to Eastern Orthodoxy, divided the lands of the Ruthenian szlachta, and became the Cossack szlachta. The uprising was one of a series of catastrophic events for the Commonwealth, known as The Deluge, which greatly weakened the Polish-Lithuanian Commonwealth and set the stage for its disintegration 100 years later. Influential relatives of the Ruthenian and Lithuanian szlachta in Moscow helped to create the Russian–Polish alliance against Khmelnitsky's Cossacks, portrayed as rebels against order and against the private property of the Ruthenian Orthodox szlachta. Don Cossacks' raids on Crimea left Khmelnitsky without the aid of his usual Tatar allies. From the Russian perspective, the rebellion ended with the 1654 Treaty of Pereyaslav, in which, in order to overcome the Russian–Polish alliance against them, the Khmelnitsky Cossacks pledged their loyalty to the Russian Tsar. In return, the Tsar guaranteed them his protection; recognized the Cossack starshyna (nobility), their property, and their autonomy under his rule; and freed the Cossacks from the Polish sphere of influence and the land claims of the Ruthenian szlachta.
Ball JC, Vander Jagt DL (1979). "Purification of S-2-hydroxyacylglutathione hydrolase (glyoxalase II) from rat erythrocytes". Anal. Biochem. 98 (2): 472–7. doi:10.1016/0003-2697(79)90169-6. PMID 496013.
== History == Studies on how people transform the substances that they ingest began in the mid-nineteenth century, with chemists discovering that organic chemicals such as benzaldehyde could be oxidized and conjugated to amino acids in the human body. During the remainder of the nineteenth century, several other basic detoxification reactions were discovered, such as methylation, acetylation, and sulfonation. In the early twentieth century, work moved on to the investigation of the enzymes and pathways that were responsible for the production of these metabolites. This field became defined as a separate area of study with the publication by Richard Williams of the book Detoxication mechanisms in 1947. This modern biochemical research resulted in the identification of glutathione S-transferases in 1961, followed by the discovery of cytochrome P450s in 1962, and the realization of their central role in xenobiotic metabolism in 1963.
In typical mass spectrometry, MS is coupled with separation tools like gas chromatography, liquid chromatography or electrophoresis to reduce the effect of the matrix or background and improve the selectivity especially when the analytes are widely different in concentration. Sample preparation including sample collection, extraction, pre-separation increases the size of the mass analysis system and adds time and sophistication to the analysis. A lot of contribution promotes miniaturizing devices and simplifying the operations. A micro-GC has been implemented to fit to a portable MS system. Besides microfluidics is a competent candidate for MMS and automating sample preparation. In this technique, most of the steps for sample preparation are staged similarly with laboratory systems, but miniature chip-based devices are used with low consumption of sample and solvents. One way to circumvent classical, lab-based sample introduction systems is the use of ambient ionization, as it does not require mechanical or electrical coupling to a MMS and can generate ions in the open atmosphere without prior sample preparation, but at the cost of more rigorous vacuum system requirements. Different ambient ionization methods, including low-temperature plasma, paper spray, and extraction spray, have been demonstrated to be highly compatible with MMS. A rigorous review of ambient ionization sources in the context of portable and miniature mass spectrometry has developed a set of criteria by which performance and portability can be evaluated.
Sources: en.wikipedia.org
Food packaging is created through the use of a wide variety of plastics and metals, papers, and glass materials. Recycling these products differs from the act of literally reusing them because the recycling process has its own algorithm, which includes collecting, sourcing, processing, manufacturing and marketing these products. According to the Environmental Protection Agency of the United States, the recycling rate has been steadily on the rise, with data reporting that, in 2018, the recycling rate of generated packaging and containers was 53.9 percent. Recycling rates for glass and metal packaging fluctuate considerably based on regional infrastructure, collection methods, and public engagement. In the European Union, glass packaging attains an average recycling rate of approximately 80%. Conversely, the United States exhibits a lower glass recycling rate of roughly 31%, mainly due to contamination and inadequate sorting capabilities. Metal packaging, especially aluminum and steel, typically has superior recycling efficiency. In the EU, aluminum beverage cans achieve recycling rates of approximately 76%. Both materials exhibit superior recycling rates and quality in comparison to plastic and paper. The product's quality and safety are the package's most important responsibility. However, there have been growing demands for packaging to be designed, manufactured, consumed, and recycled in a more sustainable fashion due to the increasing pollution connected with packaging and food waste.
In spite of this complex mixture of religious traditions, generally, the prevailing artistic style at any time and place has been shared by the major religious groups, and sculptors probably usually served all communities. Gupta art, at its peak c. 300 CE – c. 500 CE, is often regarded as a classical period whose influence lingered for many centuries after; it saw a new dominance of Hindu sculpture, as at the Elephanta Caves. Across the north, this became rather stiff and formulaic after c. 800 CE, though rich with finely carved detail in the surrounds of statues. But in the South, under the Pallava and Chola dynasties, sculpture in both stone and bronze had a sustained period of great achievement; the large bronzes with Shiva as Nataraja have become an iconic symbol of India. Ancient paintings have only survived at a few sites, of which the crowded scenes of court life in the Ajanta Caves are some of the most important. Painted manuscripts of religious texts survive from Eastern India from 10th century onwards, most of the earliest being Buddhist and later Jain. These significantly influenced later artistic styles. The Persian-derived Deccan painting, starting just before the Mughal miniature, between them give the first large body of secular painting, with an emphasis on portraits, and the recording of princely pleasures and wars. The style spread to Hindu courts, especially among the Rajputs, and developed a variety of styles, with the smaller courts often the most innovative, with figures such as Nihâl Chand and Nainsukh.
== Controversies == During the Second World War, Roche was reported to have collaborated with the Nazi regime in Germany and used prisoners-of-war or foreign forced labour in its German and Polish-based factories. In 2008 the Association of the British Pharmaceutical Industry (ABPI) suspended Roche for six months for breaching their code of conduct. In 2013, Roche had to pay back SFr 3.2 billion to the Swiss tax authorities due to transfer mispricing.
=== Cyclization of amino acids === Lactams can be formed from cyclisation of amino acids via the coupling between an amine and a carboxylic acid within the same molecule. Lactamization is most efficient in this way if the product is a γ-lactam. For example, Fmoc-Dab(Mtt)-OH, although its side-chain amine is sterically protected by extremely bulky 4-Methyltrityl (Mtt) group, the amine can still intramolecularly couple with the carboxylic acid to form a γ-lactam. This reaction almost finished within 5 minutes with many coupling reagents (e.g. HATU and PyAOP).
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.